Pirfenidone improves survival in IPF: results from a real-life study

[1] Margaritopoulos G. A.(2012)Recent advances in the pathogenesis and clinical evaluation of pulmonary fibrosis European Respiratory Review 21 48-56

[2] Romagnoli M.(2016)Cancer statistics, 2016 CA Cancer J Clin 66 7-30

[3] Poletti V.(2015)Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review Eur Respir J 46 795-806

[4] Siafakas N. M.(2016)Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy Core Evidence 11 11-22

[5] Wells A. U.(2015)An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline Am J Respir Crit Care Med 192 e3-19

[6] Antoniou K. M.(2014)A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis N Engl J Med 370 2083-2092

[7] Siegel RL(2017)Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis Lancet Respir Med 5 33-41

[8] Miller KD(2012)Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good Thorax 67 938-940

[9] Jemal A(2017)An open-label study of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (RECAP) Respiration 94 408-415

[10] Hutchinson J(2011)An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management Am J Respir Crit Care Med 183 788-824

[1] Margaritopoulos G. A.(2012)Recent advances in the pathogenesis and clinical evaluation of pulmonary fibrosis European Respiratory Review 21 48-56

[2] Romagnoli M.(2016)Cancer statistics, 2016 CA Cancer J Clin 66 7-30

[3] Poletti V.(2015)Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review Eur Respir J 46 795-806

[4] Siafakas N. M.(2016)Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy Core Evidence 11 11-22

[5] Wells A. U.(2015)An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline Am J Respir Crit Care Med 192 e3-19

[6] Antoniou K. M.(2014)A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis N Engl J Med 370 2083-2092

[7] Siegel RL(2017)Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis Lancet Respir Med 5 33-41

[8] Miller KD(2012)Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good Thorax 67 938-940

[9] Jemal A(2017)An open-label study of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (RECAP) Respiration 94 408-415

[10] Hutchinson J(2011)An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management Am J Respir Crit Care Med 183 788-824